
Diagnosis & Management of Hypertension-Preeclampsia Summary of the ACOG Hypertension in Pregnancy Task Force Sean C. Blackwell, MD Professor and Chair, Department of Obstetrics, Gynecology and Reproductive Sciences Director, Larry C. Gilstrap M.D. Center for Perinatal and Women's Health UT Health-University of Texas Medical School at Houston

• None #UTHealth The University of Floring

Changes in New Guidelines Diagnosis of preeclampsia Preeclampsia with severe features Superimposed preeclampsia Superimposed with severe features Target BP to treat Before delivery/Postpartum Indications for Magnesium Sulfate Postpartum HTN-preeclampsia Prediction, prevention, follow-up Patient education

Classification of Hypertensive Disorders • Gestational Hypertension • Preeclampsia • Preeclampsia with severe features • Chronic Hypertension • Superimposed preeclampsia • Superimposed preeclampsia with severe features • HELLP • Eclampsia



Diganosis of GHTN-Preeclampsia		
Recommendation	GHTN	Preeclampsia
HTN > 20 wks	YES	YES
Previously normotensive	YES	YES
SBP: 140-159 mmHg	YES	YES
DBP: 90-109 mmHg	YES	YES
Persistent for 4 hrs	YES	YES
Presence of sxs	NO	NO
Normal blood tests	YES	YES
Proteinuria: ≥ 300mg/24h P: C ratio ≥ 0.3 Dip stick : ≥ 1+	NO	YES
## U	THealth	

Preeclampsia & any one of the following > SBP ≥ 160 or DBP ≥ 110 mmHg • Two BP values 4 hrs apart on bed rest • Once if anti-hypertensives are used > Persistent Cerebral / Visual disturbances > Pulmonary edema > Severe persistent RUQ/epigastric pain unresponsive to RX > Low platelets <100, 000 > Elevated liver enzymes(>2x normal) > Serum creatinine >1.1 mg/dl

Removed from criteria for Severe

- Amount of proteinuria
 - 3-5 g / 24 hour
 - \geq 3+ on dipstick
- Oliguria
 - < 30 cc /hour
 - < 500 cc / 24 hour
- FGR / SGA
 - _ < 10th %
 - < 5th %


#UTHealth

Proteinuria in Preeclampsia Does the amount matter?

- No differences in outcomes ($< 5 \text{ vs} \ge 5 \text{ g}$)
 - Renal function
 - Latency
- Similar outcomes (< 5, 5-9.99, ≥ 10 g/24h)
- Delivery decision should <u>not</u> be based on:
 - Amount of proteinuria
 - Change in amount of proteinuria


DX. Of Superimposed Preeclampsia New onset proteinuria Sudden ↑ in pre-existing proteinuria Substantial? Sustained? Sudden ↑ in blood pressure if Previously well controlled or Escalation of BP medications SBP < 160 and DBP < 110 mm Hg

Superimposed Preeclampsia with Severe Features Severe hypertension despite treatment SBP> 150 or DBP > 110 mm Hg Cerebral / visual symptoms Pulmonary edema Low platelets < 100,000 Elevated liver enzymes (> 2x upper normal) Persistent RUQ/epigastric pain unresponsive to RX Serum creatinine >1.1mg (new onset)




Recommended Criteria for HELLP Syndrome • Hemolysis (at least two of these) • Peripheral smear (schistocytes, burr cells) • Serum bilirubin (≥ 1.2 mg/dl) • Low serum haptoglobin • Severe Anemia, unrelated to blood loss • Elevated liver enzymes • AST or ALT ≥ 2x upper level normal • LDH ≥ twice upper level normal* • Low platelets :<100,000/mm³ * Also elevated in severe hemolysis


Recommendation	GHTN	Preeclampsia
Best Rest	No	No
Outpatient anti hypertensive	No	No
Daily monitoring of Sxs	YES	YES
BP check	2x / wk.	2x / wk.
Protein check / wk	Yes	No
NST and AFI	1x / wk	2x / wk
EFW every	3 wk.	3 wk.
CBC, Liver enzymes, Cr	1x / wk	1x / wk
Delivery at 37 wk.	Yes	Yes




HYPITAT Randomized Trial Maternal Outcome (%)			
	Induction	Expectant	RR
	n=377	n=379	(95% C.I.)
Composite adverse outcome	31	44	0.71 (0.59-0.86)
Severe systolic HTN	15	23	0.63 (0.46-0.86)
• HELLP	1	3	
• Pulmonary edema	0	1	
• Abruptio	0	0	
• Eclampsia	0	0	
• Maternal ICU	2	4	
Cesarean section	14	19	0.75 (0.55-1.04)
	#UTHea	lth Texas	





Management of Preeclampsia with Severe Features
 ≥ 34 wk or <23 wk <p>-Delivery</p> < 34 wk <p>-Individualize</p>
UTHealth




What to Expect from Expectant Management? Pregnancy prolongation for fetal benefit 48-72 hrs (steroids) At least 1 wk (< 28 wks) 1 wk (> 28 wks) Definite risks to mother Potential risks to fetus









"You got to know when to hold' em,
Know when to fold 'em,
Know when to walk away,
Know when to run."

From Kenny Rogers' "The Gambler"

#UTHealth
National Pages | UTHealth
National Pages | UTHealth
National Pages | UTHealth

Anti-Hypertensive Therapy

Indications

▶ Before delivery

- SBP \geq 160, irrespective of DBP
 - DBP ≥ 110 (GHTN), DBP > 105 (CHTN)
- After 15-60 min (individualize)

▶Postpartum

- SBP ≥ 150 or DBP ≥ 100 (4-6 hrs. apart)
- SBP \geq 160 or DBP \geq 110 (15-60 min.)

#UTHealth

Acute Control of Severe Hypertension


- Persistent SBP ≥ 160 (15-60 min) or
- Persistent DBP ≥ 110 mmHg
- IV labetalol
 - Bolus doses 20,40, 80, 80 mg q 10 min. (max 300)
 - Continuous IV infusion (1-2 mg/min)
- IV Hydralazine : bolus
 - 5, 10, 10 mg q 20 min (max 25 mg)
- Oral nifedipine
 - 10-20 mg q 20 min (max 60 mg)


Magnesium Sulfate Prophylaxis Mild hypertension-preeclampsia: No Close observation BP Ssx of preeclampsia Use if severe features develop Severe preeclampsia-eclampsia: Yes During labor & 24-hrs. postpartum Do not stop during C/S Postpartum severe HTN / preeclampsia With symptoms

• Magnesium sulfate Loading dose: 4 or 6 g IV over 20 min. Maintenance: 2 g IV per hr x 24 hr. • If convulsions develop or recur 2 g dose of magnesium sulfate short acting agents











preeclampsia with severe features

Fetal Guidelines for delivery

- Expedited delivery (within 72 hrs)
 - Fetal distress by FHR tracing
 - BPP \leq 4 on repeat exam (4 hr.)
 - AFI < 5 cm on repeat exam
 - U/S- EFW < 5th percentile
 - Reverse umbilical artery diastolic flow
 - Labor/ROM
 - ≥ 34 weeks' gestation



Expectant Rx in Preeclampsia & FGR< 34 wk Findings Chammas Shorter prolongation :3.1 vs. 6.6 days Ganzevoort Similar prolongation :7 days in each Increased perinatal deaths in FGR :23 vs. 10% Similar prolongation :10 days in each Visser All fetal deaths with FGR at <30 wks Shear Increased maternal complications in FGR Haddad Similar days of prolongation Increased fetal death in FGR :7 vs. 1% Zero survival < 25 wk. , 30% at 25 wk. in FGR Belghiti #UTHealth

Management of HELLP Syndrome


- Similar to preeclampsia with severe features
 - Corticosteroids for fetal benefit only < 34 wk.
 - Condition stable: delay delivery for 48 hrs.
- No dexamethasone for maternal benefit
 - Antepartum
 - Postpartum

#UTHealth

Acute Onset Maternal Syndrome

- 34 year old G₃P₂
- Same partner
- Active labor at 39 wks
 - Elevated BP, (-)protein, epigastric pain
- Vaginal delivery
- Postpartum BTL
 - Severe RUQ pain & N/V
 - Acute hypotensionHELLP + DIC

 - Liver hematoma






Maternal & Fetal Syndrome


- 36 year old G₁ with infertility
 Pregnancy after IVF
- Pregnancy after IVF
 Mild GHT, (-) Protein, normal UA at 25 wk
 Severe HTN, Sxs at 26 wk
 HELLP syndrome with bleeding
 ICH with hemiplegia
 C/S → 560 g, FGR infant
 Mother & infant survive
 No residual deficit


- - No residual deficit














Physiologic Adaptations PP that Predispose to Hypertension-Preeclampsia Fluid mobilization from interstitium Volume load Sodium load Reduced colloid oncotic pressure Withdrawal of vasodilating factors PIGF, prostacyclin, NO Use of vasoactive medications Non-steroidal anti-inflammatory agents Methergine



Authors (Country)	# of cases	% PP	% Late P
Conde-Agudelo, Columbia	164	31	12
Katz, USA	53	11	6
Mattar, USA	399	28	17
Chames, USA	89	33	26
Tuffnell, UK	82	32	2
Knight, UK	214	31	NR
Andersgaard, Scandinavia	210	31	4
Zwart, Netherland	213	28	NR
Shah, USA	40	54	32





Postpartum HTN-Preeclampsia Recommendations All women with hypertensive disorders BP check at 3 days (hospital, office or home) BP check again at 5-7 days Daily Sxs. of preeclampsia No non-steroidal anti-inflammatory agents All women Education about signs / symptoms Symptoms to report Office and L&D phone

Prediction of Preeclampsia ACOG HTP Task Force

#UTHealth

A great deal of effort has been directed to predict early (1st /2nd T) later development of preeclampsia.

Although there are encouraging findings, these tests are not yet ready for clinical use:

-Demographic Factors -Biophysical Findings -Biochemical Analyses -Combination of Above


#UTHealth


Prediction of Preeclampsia ACOG HTP Task force

We recommend that clinicians not do screening to predict preeclampsia beyond taking a history to evaluate for risk factors.

- Quality of evidence: moderate
- · Strength of recommendations: strong.

Risk of Recurrent Preeclampsia			
RISK OF RECUI	Territ Preecial	iiipsia	
Author	# of Patients	Preeclampsia %	
Makkonen et al (2000)	144	14.5	
Hnat et al (2002)	598	17.9	
Trogstad et al (2004)	19,960	14.1	
Poston et al (2006)	546	22.7	
Hjartardottir et al (2006)	151	13.2	
Brown et al (2007)	383	14	
Spinnato et al (2007)	338	11.5	
Villar et al (2007)	422	27	
#	UTHealth The University of Texas		







Prevention of Recurrent Preeclampsia

- Prepregnancy
 - Weight loss to ideal BMI
 - Control of glucose in diabetes
 - Control of BP in CHTN (diet, exercise)
- Low dose aspirin (from 13 wks)

 <34 wk

 Reccurrent
- Not recommended

 - Vitamins C & E
 Fish oil, Calcium
 - Dietary salt restriction
 - Anti-HTN therapy to prevent preeclampsia



